Fundamental Analysis of NEOLEUKIN THERAPEUTICS INC(NASDAQ:NLTX) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NLTX. NLTX was compared to 588 industry peers in the Biotechnology industry. NLTX has a great financial health rating, but its profitability evaluates not so good. NLTX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

NLTX had negative earnings in the past year.

In the past year NLTX has reported a negative cash flow from operations.

In the past 5 years NLTX always reported negative net income.

NLTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of NLTX (-38.25%) is better than 63.11% of its industry peers.

NLTX has a better Return On Equity (-45.57%) than 69.12% of its industry peers.

		Industry Rank	Sector Rank
ROA	-38.25%
ROE	-45.57%
ROIC	N/A

ROA(3y)-34.21%

ROA(5y)-38.12%

ROE(3y)-40.31%

ROE(5y)-42.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NLTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, NLTX has about the same amount of shares outstanding.

NLTX has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, NLTX has a worse debt to assets ratio.

2.2 Solvency

NLTX has an Altman-Z score of -6.37. This is a bad value and indicates that NLTX is not financially healthy and even has some risk of bankruptcy.

NLTX has a worse Altman-Z score (-6.37) than 71.29% of its industry peers.

NLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.37

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 15.37 indicates that NLTX has no problem at all paying its short term obligations.

NLTX has a Current ratio of 15.37. This is amongst the best in the industry. NLTX outperforms 89.32% of its industry peers.

A Quick Ratio of 15.37 indicates that NLTX has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 15.37, NLTX belongs to the best of the industry, outperforming 89.48% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	15.37
Quick Ratio	15.37

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for NLTX have decreased strongly by -136.78% in the last year.

EPS 1Y (TTM)-136.78%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q65.83%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 23.36% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y93.72%

EPS Next 2Y40.24%

EPS Next 3Y23.36%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NLTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NLTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NLTX's earnings are expected to grow with 23.36% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.24%

EPS Next 3Y23.36%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NLTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEOLEUKIN THERAPEUTICS INC

NASDAQ:NLTX (12/18/2023, 7:15:14 PM)

After market: 3.42 -0.07 (-2.01%)

3.49

+0.05 (+1.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap30.71M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-38.25%
ROE	-45.57%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.37
Quick Ratio	15.37
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-136.78%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y93.72%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NEOLEUKIN THERAPEUTICS INC (NLTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens